Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota

Genes (Basel). 2020 Dec 30;12(1):41. doi: 10.3390/genes12010041.

Abstract

The aim was to describe the safety of indefinite administration of antibiotics, the so-called suppressive antibiotic therapy (SAT) and to provide insight into their impact on gut microbiota. 17 patients with SAT were recruited, providing a fecal sample. Bacterial composition was determined by 16S rDNA massive sequencing, and their viability was explored by PCR-DGGE with and without propidium monoazide. Presence of antibiotic multirresistant bacteria was explored through the culture of feces in selective media. High intra-individual variability in the genera distribution regardless of the antibiotic or antibiotic administration ingestion period, with few statistically significant differences detected by Bray-Curtis distance-based principle component analysis, permutational multivariate analysis of variance and linear discriminant analysis effect size analysis. However, the microbiota composition of patients treated with both beta-lactams and sulfonamides clustered by a heat map. Curiously, the detection of antibiotic resistant bacteria was almost anecdotic and CTX-M-15-producing E. coli were detected in two subjects. Our work demonstrates the overall clinical safety of SAT and the low rate of the selection of multidrug-resistant bacteria triggered by this therapy. We also describe the composition of intestinal microbiota under the indefinite use of antibiotics for the first time.

Keywords: PCR-DGGE; antibiotic multirresistant colonization; bacterial viability; gut microbiota; propidium monoazide; suppressive antibiotic therapy.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aminoglycosides / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Arthroplasty, Replacement, Hip / adverse effects
  • Arthroplasty, Replacement, Knee / adverse effects
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / etiology
  • Bacterial Infections / microbiology
  • Drug Resistance, Multiple, Bacterial / genetics
  • Enterobacter cloacae / drug effects
  • Enterobacter cloacae / genetics
  • Enterobacter cloacae / metabolism
  • Escherichia coli / drug effects
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Feces / microbiology
  • Female
  • Fluoroquinolones / therapeutic use
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / genetics
  • Glycopeptides / therapeutic use
  • Humans
  • Macrolides / therapeutic use
  • Male
  • Microbial Sensitivity Tests
  • Prospective Studies
  • Prosthesis-Related Infections / complications
  • Prosthesis-Related Infections / drug therapy*
  • Prosthesis-Related Infections / microbiology
  • RNA, Ribosomal, 16S / genetics
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / genetics
  • Staphylococcus aureus / metabolism
  • beta-Lactams / therapeutic use

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Glycopeptides
  • Macrolides
  • RNA, Ribosomal, 16S
  • beta-Lactams